Dermatology

A newly-discovered eczema subtype may be linked to asthma and allergies.

Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.

Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Patients with severe psoriasis were 64% more likely to develop diabetes than control patients.

Adhering to breastfeeding guidelines could cut the risk of eczema for offspring in half.

The type of inflammatory condition may increase the risk of liver disease, despite similar treatment.

The efficacy and safety of an adalimumab biosimilar matched the reference products in switching studies treating plaque psoriasis and rheumatoid arthritis.

Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.

New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.

Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.

Patients with active psoriatic arthritis experience significant work instability based on disease activity.

Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.

Top news of the week from Specialty Pharmacy Times.

A fire ant toxin may lead to new medications for psoriasis.

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.

Findings may lead to future treatments for patients with psoriasis and psoriatic arthritis.

All doses of atopic dermatitis drug achieved significant improvements in skin and itch conditions.

New ulcerative colitis and Crohn’s disease cases were uncommon in plaque psoriasis patients administered ixekizumab.

Lebrikizumab is a monoclonal antibody designed to specifically target interleukin 13 for patients with moderate-to-severe atopic dermatitis.

Lebrikizumab is a monoclonal antibody designed to treat atopic dermatitis.

Novel treatment effective against rheumatoid arthritis also produced a marked improvement in skin lesions caused by atopic dermatitis.

Adalimumab (Humira) biosimilar being tested as an interchangeable drug for plaque psoriasis.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Tremfya is the first and only approved biologic that selectively blocks the interleukin-23 protein.

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Top articles of the week from Specialty Pharmacy Times.

Study will examine the safety and efficacy of tralokinumab monotherapy in treating atopic dermatitis.